Revenue of KRW 74.3bn, operating profit of KRW 24bn, and net income of KRW 22.7bn…15.4%, 29.5%, and 33.8% YoY growth Steady growth across all product lines, including botulinum toxin, HA fillers, and cosmetics, in both home and abroad markets SEOUL, South Korea, May 9, 2024 /PRNewswire/…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.